A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 1, Iss. 1, 2011-06 ,pp. : 163-179

Karger

Access to resources Recommend Favorite

Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: A randomized, placebo-controlled, double-blind clinical trial

By Brinkhaus Benno   Hentschel Christian   Keudell Christoph Von   Schindler Gernot   Lindner Martin   Stützer Hartmut   Kohnen Ralf   Willich Stefan   Lehmacher Walter   Hahn Eckhart G.  

Scandinavian Journal of Gastroenterology, Vol. 40, Iss. 8, 2005-08 ,pp. : 936-943

Informa Healthcare

Access to resources Recommend Favorite

Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome – a pilot study

By Tuteja Ashok K.   Fang John C.   Al-Suqi Manal   Stoddard Gregory J.   Hale Devon C.  

Scandinavian Journal of Gastroenterology, Vol. 47, Iss. 10, 2012-10 ,pp. : 1159-1164

Informa Healthcare

Access to resources Recommend Favorite

The AMPA Antagonist ZK 200775 in Patients with Acute Ischaemic Stroke: A Double-Blind, Multicentre, Placebo-Controlled Safety and Tolerability Study

By  

Cerebrovascular Diseases, Vol. 20, Iss. 5, 2005-11 ,pp. : 304-309

Karger

Access to resources Recommend Favorite

A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome

By Matsueda Kei   Harasawa Shigeru   Hongo Michio   Hiwatashi Nobuo   Sasaki Daisuke  

Scandinavian Journal of Gastroenterology, Vol. 43, Iss. 10, 2008-01 ,pp. : 1202-1211

Informa Healthcare

Access to resources Recommend Favorite